Cohesion Bureau

Precision Medicine Online, a leading pharmaceutical magazine, presented PolTREG to its U.S. readers in a broad-ranging interview with CEO Prof Piotr Trzonkowski. PolTREG’s investigational Treg therapies “could halt progression, or possibly even cure some patients with type 1 diabetes”, is how the magazine put it. Much of the interview focused on PolTREG’s Phase 2 clinical trial in presymptomatic diabetes patients, children for whom PolTREG hopes its treatment with its cellular therapy may mean they stay in clinical remission for the rest of their lives. But reporter Jessica Kim Cohen also talked about PolTREG’s future plans to develop therapies for auto-immune diseases like multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and amyotrophic lateral sclerosis. For a look at the story, click here (subscription required): https://lnkd.in/dZp5sBvm #T1D #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes #multiplesclerosis

Join us for the PolTREG Q3 2024 financial results webinar! We are pleased to invite you to our upcoming webinar, which will present the financial results for Q3 2024 and PolTREG's development plans.   Join us on Friday, November 22, 2024, at 2:00 PM CEST, where you will hear directly from our company's management:    • Piotr Trzonkowski, Co-founder and CEO  • Mariusz Jablonski, Member of the Management Board  • Dan Shelly, Chief Business Development Officer  • Marcin Kądziela, Financial controller   The webinar will be conducted in Polish and partially in English.   Register for free: https://lnkd.in/dW3FP2iP #T1D #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes #IR #investorrelations

We are thrilled to announce that AC Immune and Takeda have won the #Deal of the Year (>€500M) at the European Lifestars Awards - Celebrating Life Science Leaders. This recognition highlights our transformative license and option agreement centered on ACI-24.060, our active immunotherapy candidate targeting toxic forms of amyloid beta in Alzheimer’s disease. Currently under evaluation in the ABATE Phase 1b/2 trial, ACI-24.060 has also received Fast Track designation from the U.S. FDA, emphasizing its potential to address this critical unmet medical need. This #partnership with Takeda embodies our commitment to pioneering precision prevention for neurodegenerative diseases. Thank you to our dedicated team at AC Immune and our partners at Takeda for making this possible. Together, we will reshape the future of #Alzheimer’s #treatment and #prevention. #Neurodegeneration #PrecisionMedicine #Award #Biotech #Biopharma

Join AC Immune’s Management Team for a fireside chat at the #Jefferies London #Healthcare #Conference 2024 to get the latest updates on our clinical-stage active immunotherapy pipeline for neurodegenerative diseases. Follow this link to the webcast: https://lnkd.in/eM_KJikn #Alzheimers #Prevention  #ActiveImmunotherapy #JefferiesHealthcare #Conference

Good news for PolTREG’s plans to develop next-generation engineerd Treg cells: we just received a new patent from China for our anti-gen specific Tregs cellular therapy. The patent is for the process of manufacturing antigen-specific T-reg cells, one of several modalities of engineered Treg cells PolTREG is working on. Antigen specific Treg cells have been “trained” to recognize a patient’s biomarkers for a disease – for instance type 1 diabetes – and the expectation is this will make them more targeted as they go about their task of regulating the immune system. PolTREG’s programme with polyclonal cells is the most advanced, but we are also developing all types of engineered Treg cells, including TCR-Tregs and CAR-Tregs. In September, we announced the launch of a study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. We expect the data from this study by March 30, 2025, and will then think about the pathway to clinical evaluation. #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #t1d #diabetes

We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!     Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.     “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of therapeutic and imaging agents to enhance their efficacy,” says Alexandre Tokay, co-founder and CEO of Vect-Horus    Click here for the full press release 👉 https://lnkd.in/dz_vRb8D   #leadership #biotech #strategy #technology #science 

MITAZALIMAB IN THE NEWS. Following Alligator Bioscience AB latest mitazalimab update including 18 months survival data at last week's SITC #cancernetworks nice summarized the data in the relevance for patients suffering from metastatic pancreatic cancer. #mitazalimab #pancreaticcancer #mpdac #phase2 #immunooncology #cancer #antibody #SITC #antibody #alligator Society for Immunotherapy of Cancer (SITC)

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞: Sweden's Alligator Bioscience AB is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward. CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x 5T4 bispecifics the company is developing. Full video: https://lnkd.in/gM5hTQ78 BiotechTV's coverage of #BIOEurope 2024 is brought to you by Pareto Securities. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh